Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This study recommends the use of OnLife dietary supplement, which will be followed by a few
day before the initiation of PACLITAXEL, for the prevention of PACLITAXEL induced neuropathy.
OnLife will be continued one month after stopping chemotherapy.
This would limit the number of PACLITAXEL dose reductions and premature interruptions of this
chemotherapy, thus potentially improving the results in terms of antitumor efficacy, while
improving the quality of life of patients treated with weekly PACLITAXEL.